Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:CAPR NYSE:NUVB NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$29.40-3.4%$29.68$22.24▼$46.00$1.81B0.58794,834 shs1.43 million shsCAPRCapricor Therapeutics$29.96+2.9%$31.48$4.30▼$40.37$1.69B0.481.06 million shs841,137 shsNUVBNuvation Bio$4.76+0.2%$4.62$1.57▼$9.75$1.65B1.514.32 million shs4.20 million shsPRTCPureTech Health$17.42$16.93$14.50▼$19.92$424.04M1.1518,480 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-3.35%+4.48%+4.81%-2.75%-4.64%CAPRCapricor Therapeutics+2.92%+3.78%-7.70%+7.27%+181.31%NUVBNuvation Bio+0.49%+0.74%+9.55%-19.53%+117.35%PRTCPureTech Health0.00%0.00%+0.11%+3.88%-2.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$29.40-3.4%$29.68$22.24▼$46.00$1.81B0.58794,834 shs1.43 million shsCAPRCapricor Therapeutics$29.96+2.9%$31.48$4.30▼$40.37$1.69B0.481.06 million shs841,137 shsNUVBNuvation Bio$4.76+0.2%$4.62$1.57▼$9.75$1.65B1.514.32 million shs4.20 million shsPRTCPureTech Health$17.42$16.93$14.50▼$19.92$424.04M1.1518,480 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-3.35%+4.48%+4.81%-2.75%-4.64%CAPRCapricor Therapeutics+2.92%+3.78%-7.70%+7.27%+181.31%NUVBNuvation Bio+0.49%+0.74%+9.55%-19.53%+117.35%PRTCPureTech Health0.00%0.00%+0.11%+3.88%-2.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.4440.97% UpsideCAPRCapricor Therapeutics 2.80Moderate Buy$48.3661.43% UpsideNUVBNuvation Bio 2.55Moderate Buy$12.50162.61% UpsidePRTCPureTech Health 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PRTC, AGIO, CAPR, and NUVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $40.005/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/18/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026CAPRCapricor Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/13/2026CAPRCapricor Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/5/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.005/5/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.005/5/2026NUVBNuvation Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/21/2026NUVBNuvation Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M32.36N/AN/A$18.65 per share1.58CAPRCapricor Therapeutics$22.27M77.91N/AN/A$4.81 per share6.23NUVBNuvation Bio$62.90M26.35N/AN/A$0.92 per share5.17PRTCPureTech Health$4.66M91.01N/AN/A$12.65 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)CAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)PRTCPureTech Health-$109.74MN/AN/AN/AN/AN/AN/AN/AN/ALatest PRTC, AGIO, CAPR, and NUVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million4/10/2026H2 2025PRTCPureTech HealthN/A-$1.35N/A-$1.35N/A$1.40 million3/12/2026Q4 2025CAPRCapricor Therapeutics-$0.51-$0.62-$0.11-$0.62$0.53 millionN/A3/2/2026Q4 2025NUVBNuvation Bio-$0.11-$0.11N/A-$0.11$36.82 million$41.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59CAPRCapricor TherapeuticsN/A8.428.42NUVBNuvation Bio0.157.447.24PRTCPureTech HealthN/A6.596.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACAPRCapricor Therapeutics21.68%NUVBNuvation Bio61.67%PRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%CAPRCapricor Therapeutics9.20%NUVBNuvation Bio30.11%PRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionablePRTCPureTech Health10024.34 million23.05 millionNot OptionablePRTC, AGIO, CAPR, and NUVB HeadlinesRecent News About These CompaniesPureTech to Showcase Deupirfenidone Program at the American Thoracic Society International ConferenceMay 13, 2026 | businesswire.comPureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPOMay 1, 2026 | proactiveinvestors.co.ukPureTech Announces Annual Results for Year Ended December 31, 2025April 29, 2026 | businesswire.comPureTech Health: Notice of ResultsApril 13, 2026 | businesswire.comPureTech Gains on ResultsApril 2, 2026 | baystreet.caPureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care MedicineApril 2, 2026 | businesswire.comPureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansMarch 25, 2026 | businesswire.comPureTech to Present at the Leerink Partners Global Healthcare ConferenceFebruary 25, 2026 | businesswire.comPureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisFebruary 19, 2026 | businesswire.comPureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comPureTech to Present at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2026 | finance.yahoo.comPureTech CEO to present at JP Morgan Healthcare ConferenceJanuary 6, 2026 | msn.comPureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the companyJanuary 3, 2026 | finance.yahoo.comPureTech Appoints Robert Lyne as Chief Executive OfficerDecember 18, 2025 | businesswire.comPeel Hunt Limited reiterates PureTech Health plc - Depositary Receipt (PRTC) buy recommendationDecember 16, 2025 | msn.comPureTech stock falls after FDA meeting on IPF drugDecember 8, 2025 | in.investing.comPureTech Health completes LYT-100 end-of-phase 2 meeting with FDADecember 8, 2025 | msn.comPureTech slides after FDA meeting outlines next steps for IPF programDecember 8, 2025 | msn.comPuretech gains after FDA meeting post-Phase II trialDecember 8, 2025 | proactiveinvestors.co.ukPureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisDecember 8, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTC, AGIO, CAPR, and NUVB Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$29.40 -1.02 (-3.35%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$29.37 -0.03 (-0.12%) As of 05/29/2026 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Capricor Therapeutics NASDAQ:CAPR$29.96 +0.85 (+2.92%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$29.80 -0.16 (-0.53%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Nuvation Bio NYSE:NUVB$4.76 +0.01 (+0.21%) Closing price 05/29/2026 03:59 PM EasternExtended Trading$4.70 -0.06 (-1.34%) As of 05/29/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.PureTech Health NASDAQ:PRTC$17.42 0.00 (0.00%) As of 05/28/2026PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
